<DOC>
	<DOC>NCT00800722</DOC>
	<brief_summary>The purpose of this study is to improve port wine stain therapeutic outcome in response to laser therapy. The researchers want to determine whether the combined use of pulsed dye laser therapy and rapamycin will improve PWS therapeutic outcome.</brief_summary>
	<brief_title>A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.</brief_title>
	<detailed_description>The researchers want to combined use of pulsed dye laser to induce port wine stain blood vessel injury, and rapamycin directly inhibits the proliferation of vascular endothelial cells driven by vascular endothelial growth factor which preventing port wine stain angiogenesis and recanalization, to improve port wine stain lesion blanching.</detailed_description>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Hemangioma, Capillary</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>port wine stain birthmarks suitable for comparison testing. Pregnancy. Abnormal blood hematology or chemistry blood tests or urine analysis. History of cancer, History of high cholesterol, lipids or liver disease Allergy to macrolide drugs (e.g., erythromycin). Any therapy within the previous two months to the proposed PWS treatment sites. Concurrent use of known photosensitizing drugs,immunosuppressive drugs or systemic steroids,antifungals, antiepileptics, HIV protease inhibitors, cimetidine, cisapride, clarithromycin, dannzol, diltiazem, erythromycin, metoclopramide, rifabutin, rifampin, rifapentine, troleandomycin, or verapamil.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hypervascular anomalies</keyword>
</DOC>